Patients or their clinical team can use the platform independently, on their computer, tablet or cell phone. At regular intervals, patients complete a monitoring questionnaire specific to their treatment or protocol.
After analysis of the responses by our medical device, an alert is generated for the care teams, and an appropriate guidance message is sent to the patient, along with therapeutic advice to help manage grade 1 and 2 adverse events.
Patient information content and digital supportive care are also accessible via the app.
For the few patients who cannot or do not wish to use the application, a phone monitoring module is available.
A member of the care team can enter the patients responses to the questionnaire during a phone call with the patient.
Following analysis of the responses by our medical device, an alert is generated for the care teams. The entire patient cohort can thus be remotely monitored via our platform.
The “OK-Chemo” module collates patients’ reported toxicities and blood test results one or two days before their scheduled appointments.
This is used to pre-validate patients’ chemotherapy appointments at the outpatient department.
Precise symptom monitoring and proactive management
Scheduling a visit in day hospital
Consultation support
Detecting symptoms before consultations
Improved quality
of life
Reduced risk of hospitalization
Improved life expectancy
Improving cancer patient care with a digital telemonitoring platform: The ConnectPatientToDoctor study
Helissey, Duverger, et al. Journal of Clinical Oncology 2021;39:15_suppl:1581. doi: 10.1200/JCO.2021.39.15_suppl.1581
Effectiveness of a digital telemonitoring platform for elderly cancer patient (EP) care
Helissey, Duverger, et al. Annals Oncol 2021;32(S5):S1187. doi: 10.1016/j.annonc.2021.08.1675
Electronic patient-reported outcomes are a promising predictive factor of prostate cancer patient survival: The Protecty study
Helissey, Riviere, et al. Journal of Clinical Oncology 2022 Feb 20;40(6_suppl):76. doi:10.1200/JCO.2022.40.6_suppl.076
Early Patient-Reported Outcomes Are a Promising Predictive Factor of Cancer Progress and Outcome in Older Patients: The EPROFECY Study.
Helissey, Riviere, et al. Journal of Clinical Oncology 2022 June 1;40(16_suppl):12045. doi:10.1200/JCO.2022.40.16_suppl.12045
A study to assess the diagnostic performance of a digital remote monitoring tool for cancer patients: the POSITEA-VA study.
Parnot, Montestruc. Journal of Clinical Oncology 2023 Jun 1;41(16_suppl):1605. doi:10.1200/JCO.2023.41.16_suppl.1605
The Use of Telemedicine in Cancer Clinical Trials: Connect-Patient-to-Doctor Prospective Study
Meghiref, Parnot, et al. JMIR Cancer 2022 Jan 27;8(1):e31255. doi:10.2196/31255
Effectiveness of a digital telemonitoring platform for cancer care of older patients: The ConnectElderlyPatientToDoctor study
Rivière, Brureau,et al. Int J Cancer. 2023 Feb 1;152(3):504-510. doi:10.1002/ijc.34196
Effectiveness of electronic patient reporting outcomes, by a digital telemonitoring platform, for prostate cancer care: the Protecty study
Helissey, Parnot, et al.
Front. Digit. Health 2023 May 8;5:1104700. doi:10.3389/fdgth.2023.1104700
Dr. Noémie STUDDER, support care and patient pathways manager
Joana ROSE, coordinating nurse
Dr. Thomas FEUTREN, radiotherapist oncologist
